Pneumococcal otitis media and pneumococcal vaccines, a historical perspective

Vaccine

Volumn 19, Issue SUPPL. 1, 2000, Pages

  Austrian, Robert ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

History; Pneumococcal otitis media; Pneumococcal vaccines

Indexed keywords

ANTIBODY; AUTOLYSIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; GALACTOSE; GLUCOSE; INACTIVATED VACCINE; MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN; PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; PROTEIN PSP A; SIALIDASE; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CLINICAL TRIAL; DRUG CONJUGATION; DRUG EFFICACY; EPIDEMIC; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFECTION PREVENTION; LOBAR PNEUMONIA; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINE PRODUCTION;

EID: 0034623908     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00282-6     Document Type: Short Survey

References (71)

1. Mikrooganismen im secrete der Otitis media acuta
2. Temporal bone preservation in a 2600-year-old Egyptian mummy
3. Middle ear disease in a prehistoric Iranian population
4. A fatal form of septicaemia in the rabbit, produced by the subcutaneus injection of human saliva. An experimental research
5. Note sur la maladie nouvelle provoquée par la salive d'un enfant mort de la rage
6. Untersuchungen über das auftreten und bedeutung von coccobakterien bei eiterigem ohrenfluss und die durch gegenwart bedingten therapeutischen indikationen
7. De la méningite due au pneumocoque (avec ou sans pneumonie) (1)
8. Weitere mittheilung über das vorkommen von mikroorganismen im secrete der Otitis media acuta (genuina)
9. Recherches bactériologiques sur les otites moyennes aigues
10. A bacteriological investigation of the suppurative ear discharge occuring as a complication of scarlet fever
11. Scarlet fever
12. The primary infection in acute suppuration of the tympanum
13. Ueber ein speifische bakteriolytische wirkung der galle
14. A contribution to the physiological differentiation of pneumococcus and streptococcus, and to methods of staining capsules
15. Die artunterscheidung der für den menschen pathogenen streptokokken durch blutagar
16. A biologic classification of pneumococci by means of immunity reactions
17. An immunological study of Pneumococcus mucosus
18. Clinico-bacteriologic studies on acute otitis media
19. Defining the public health impact of Streptococcus pneumoniae: Report of a working group
20. Of gold and pneumococci. A history of pneumococcal vaccines in South Africa
21. Observations on prophylactic inoculation against pneumococcus infection and on the results which have been achieved by it
22. An inquiry into the etiology, manifestations and prevention of pneumonia amongst natives on the Rand recruited from tropical areas
23. An experimental study of prophylactic inoculation against pneumococcal infection in the rabbbit and in man
24. Antibody formation in volunteers following injection of pneumococci or their type-specific polysaccharides
25. Soluble substance of pneumococcus origin in the blood and urine during lobar pneumonia
26. The elaboration of specific soluble substance by pneumococcus during growth
27. The specific soluble substance of pneumococcus
28. Sind die spezifisch präcipitabelen substanzen der 3 pneumokokkentypen haptene?
29. Weitere untersuchungen mit dem kohlenhydrat aus Typ-II-Pneumokokken
30. Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide
31. Specific cutaneous reactions and circulating antibodies in the course of lobar pneumonia. I. Cases receiving no serum therarpy
32. Studies on immunizing substances in pneumococci. VIII. Report on field tests to determine the prophylatic value of a pneumococcus antigen
33. Prevention of pneumococcal pneumonia by immunization
34. Pneumoccocal bacteremia with special reference to bacteremic pneumococcal pneumonia
35. Prevention of pneumococcal pneumonia by vaccination
36. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious infection
37. Pneumococcal vaccine efficacy in selected populations in the United States
38. The clinical effectiveness of pneumococcal vaccine in the elderly
39. The protective efficacy of pneumococcal polysaccharide vaccine
40. Experimental otitis media due to Streptococcus pneumoniae: Immunopathogenic response in the chinchilla
41. Modification of otitis media following vaccination with the capsular polysaccharide of Streptococcus pneumoniae in chinchillas
42. The pathogenesis of pneumococcal otitis media in chinchillas and the efficacy of vaccination in prophylaxis
43. Prevention of pneumococcal otitis media in chinchillas with human bacterial polysaccharide immune globulin
44. Clinical studies of pneumococcal vaccines in infants. II. Efficacy and effect on nasal carriage
45. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in Boston
46. Efficacy of pneumococcal polysaccharide vaccine in preventing acute otitis media in infants in Huntsville, AL
47. A study of pneumococcal vaccine in prevention of clinically acute attacks of recurrent otitis media
48. Antibody response to pneumococcal vaccine in children younger than 5 years of age
49. Pneumoccocal vaccine in normal children
50. The response of infants to inoculation with type 1 pneumococcus carbohydrate
51. Studies on immunizing substances in pneumococci. VII. Response in human beings to antigenic pneumococcus polysaccharides
52. Development of antibody following vaccination of infants and children against pneumococci
53. Thymus-dependent and thymus-independent populations: Origin, migratory patterns and lifespan
54. Thymus-independent antigens: Complexity of B-lymphocyte activation revealed
55. Thymus-independent and thymus-dependent antigens
56. Immunological reactions of the isolated carbohydrate and protein of pneumococcus
57. Chemo-immunological studies on carbohydrate-proteins. I. The synthesis of p-aminophenol β-glucoside, p-aminophenol β-galactoside and their coupling to serum globulin
58. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens
59. Chemo-immunological studies on conjugated carbohydrate-proteins. IV. The synthesis of the p-aminobenzyl ether of the specific soluble substance of type III pneumococcus and its coupling to protein
60. Chemo-immunological studies on conjugated carbohydrate-proteins. ∇. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein
61. Chemo-immunological studies on conjugated-carbohydrate proteins. XII. The immunological properties of an artificial antigen containing cellobiuronic acid
62. Studies on antibacterial immunity induced by artificial antigens. I. Immunity to experimental pneumococcal infection with an antigen containing cellobiuronic acid
63. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates
64. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b
65. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1
66. Pneumococcal conjugate vaccines
67. Reduction in nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine
68. Efficacy of a heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37 000 infants and children: Results of the Northern California Kaiser Permanente Trial
69. Pneumococcal diversity: Considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PSP A)